Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) has earned a consensus recommendation of “Moderate Buy” from the seven brokerages that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, two have given a hold rating, three have issued a buy rating and one has issued a strong buy rating on the company. The average twelve-month price target among brokers that have covered the stock in the last year is $17.75.

Several equities analysts have issued reports on ATRA shares. RODMAN&RENSHAW cut shares of Atara Biotherapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 21st. Canaccord Genuity Group dropped their price objective on shares of Atara Biotherapeutics from $21.00 to $17.00 and set a “buy” rating on the stock in a research note on Friday, January 17th. Rodman & Renshaw started coverage on shares of Atara Biotherapeutics in a research note on Friday, December 20th. They issued a “buy” rating and a $25.00 price objective on the stock. HC Wainwright reissued a “neutral” rating on shares of Atara Biotherapeutics in a research note on Tuesday, January 28th. Finally, TD Cowen raised shares of Atara Biotherapeutics to a “strong-buy” rating in a research note on Friday, November 29th.

Atara Biotherapeutics Trading Up 0.4 %

ATRA stock opened at $9.34 on Friday. Atara Biotherapeutics has a twelve month low of $5.40 and a twelve month high of $28.75. The company’s 50 day moving average is $11.50 and its two-hundred day moving average is $9.84. The stock has a market cap of $53.80 million, a P/E ratio of -0.36 and a beta of 0.46.

Atara Biotherapeutics (NASDAQ:ATRA) last released its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($2.93) earnings per share for the quarter, topping analysts’ consensus estimates of ($3.77) by $0.84. The company had revenue of $40.19 million for the quarter, compared to analyst estimates of $23.00 million. During the same period in the previous year, the business posted ($16.50) EPS. On average, equities research analysts predict that Atara Biotherapeutics will post -10.39 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Geode Capital Management LLC increased its position in Atara Biotherapeutics by 9.5% during the 3rd quarter. Geode Capital Management LLC now owns 46,720 shares of the biotechnology company’s stock worth $380,000 after purchasing an additional 4,043 shares in the last quarter. State Street Corp increased its position in Atara Biotherapeutics by 52.3% during the 3rd quarter. State Street Corp now owns 22,353 shares of the biotechnology company’s stock worth $182,000 after purchasing an additional 7,680 shares in the last quarter. FMR LLC increased its position in Atara Biotherapeutics by 41.7% during the 3rd quarter. FMR LLC now owns 25,061 shares of the biotechnology company’s stock worth $204,000 after purchasing an additional 7,381 shares in the last quarter. Cubist Systematic Strategies LLC acquired a new stake in Atara Biotherapeutics during the 2nd quarter worth approximately $79,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in Atara Biotherapeutics during the 2nd quarter worth approximately $53,000. Institutional investors and hedge funds own 70.90% of the company’s stock.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.